Kolmar BNH Sharpens Global Competitiveness with Dual Functionality of HemoHIM
June 21 2024 - 2:00AM
Business Wire
Kolmar BNH (KOSDAQ: 200130), a leading Original Development
Manufacturing (ODM) company for health functional foods,
strengthens its market position by acquiring certification for the
additional functionality of HemoHIM, a renowned Korean health
supplement.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240620376394/en/
HemoHIM G, manufactured by Kolmar BNH and
distributed by Atomy, contains Angelica sinensis, Ligusticum
chuanxiong, and Paeonia lactiflora. It was launched in Taiwan last
month. (Photo: Kolmar BNH)
The company secured approval from the Ministry of Food and Drug
Safety for the fatigue-improving function of the HemoHIM extract
complex of angelica gigas, etc., derived from angelica gigas and
other components in 2023. This achievement was made six years after
the launch of its HemoHIM Sustainable Technology Development
Project. As a result, HemoHIM came to the market as a
dual-functional health product designed to boost immune function
and reduce fatigue.
HemoHIM, developed by Kolmar BNH in 2006, is the nation’s first
individually-approved immune-boosting health supplement, formulated
using indigenous natural ingredients like angelica gigas, cnidium
officinale, and paeonia japonica. Distributed by Atomy, it's now a
global success, exported to over 20 countries and generating over
KRW 2 trillion in sales with exports exceeding $200 million. It has
remained Korea's top-selling immune booster for over a decade.
Kolmar BNH validated the fatigue improvement function of HemoHIM
through extensive clinical (human trials) and non-clinical trials
(cell tests). In trials involving adults aged 30 to 59 experiencing
fatigue, significant enhancements were observed in fatigue
measures, including the Fatigue Severity Scale (FSS) and
Multidimensional Fatigue Inventory (MFI), following consumption of
the HemoHIM extract complex of angelica gigas, etc. These findings
were published in Phytomedicine Plus, an international journal
dedicated to natural medicine, with patents registered in Korea and
Russia.
Continuing its commitment to innovation following the launch of
HemoHIM, Kolmar BNH allocates over 2% of its annual sales to
R&D. This investment aims to enhance product functionality and
fortify competitive advantage.
HemoHIM G, targeting the global market, is one of the results of
such dedication to R&D. Launched in Taiwan last month, HemoHIM
G is a new product for export that has made meticulous adjustments
to its raw materials and ingredient proportions to comply with
international food regulations. Its key ingredients such as
Angelica sinensis, Ligusticum chuanxiong, and Paeonia lactiflora
went through rigorous sourcing procedures and stringent quality
control. The taste and aroma profiles were tailored to suit the
preferences of global consumers. Furthermore, its safety has been
certified in the prestigious academic journal “Toxicological
Research”, accredited at the SCIE level.
Kolmar BNH official said, "Through relentless research and
development efforts, Kolmar BNH has enhanced the competitiveness of
HemoHIM. We are dedicated to promoting K-health functional food
globally through ongoing innovations in HemoHIM."
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240620376394/en/
Kolmar BNH Jang Woo Lee jay.lee@kolmar.co.kr